ES2085928T3 - Gen y secuencia proteica del mk humano. - Google Patents

Gen y secuencia proteica del mk humano.

Info

Publication number
ES2085928T3
ES2085928T3 ES91108943T ES91108943T ES2085928T3 ES 2085928 T3 ES2085928 T3 ES 2085928T3 ES 91108943 T ES91108943 T ES 91108943T ES 91108943 T ES91108943 T ES 91108943T ES 2085928 T3 ES2085928 T3 ES 2085928T3
Authority
ES
Spain
Prior art keywords
human
gen
protein sequence
protein
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91108943T
Other languages
English (en)
Inventor
Imre Kovesdi
Peter Bohlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2085928T3 publication Critical patent/ES2085928T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVAS SECUENCIAS DE AMINAS Y ADN PARA UNA PROTEINA MK HUMANA. TAMBIEN SE DESCRIBEN LOS VECTORES DE EXPRESION Y CELULAS HUESPED UTILES EN UN METODO PARA LA PRODUCCION DE LA PROTEINA MK.
ES91108943T 1990-08-20 1991-05-31 Gen y secuencia proteica del mk humano. Expired - Lifetime ES2085928T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56857390A 1990-08-20 1990-08-20
US07/650,795 US5210026A (en) 1990-08-20 1991-02-05 Human mk gene and method of expression

Publications (1)

Publication Number Publication Date
ES2085928T3 true ES2085928T3 (es) 1996-06-16

Family

ID=27074824

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91108943T Expired - Lifetime ES2085928T3 (es) 1990-08-20 1991-05-31 Gen y secuencia proteica del mk humano.

Country Status (13)

Country Link
US (1) US5210026A (es)
EP (1) EP0476233B1 (es)
JP (1) JPH06217778A (es)
KR (1) KR920004570A (es)
AT (1) ATE134219T1 (es)
AU (1) AU636789B2 (es)
CA (1) CA2049370A1 (es)
DE (1) DE69117123T2 (es)
DK (1) DK0476233T3 (es)
ES (1) ES2085928T3 (es)
GR (1) GR3019059T3 (es)
NZ (1) NZ239357A (es)
PT (1) PT98694A (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
GB9225928D0 (en) * 1992-12-11 1993-02-03 Cancer Res Campaign Tech Growth factor
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
JP3906314B2 (ja) * 1994-04-25 2007-04-18 ジェネンテク・インコーポレイテッド カルジオトロフィンおよびその使用
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US7258983B2 (en) * 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
JPH0995454A (ja) * 1995-10-02 1997-04-08 Meiji Milk Prod Co Ltd 抗潰瘍組成物
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
ATE299030T1 (de) * 1996-07-10 2005-07-15 Meiji Dairies Corp Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
AU738923C (en) 1997-03-12 2003-02-20 Takashi Muramatsu Preventive and therapeutic compositions for drug induced nephropathy and hepatopathy
AU756279B2 (en) * 1997-07-14 2003-01-09 Medical Therapies Limited Agents comprising Midkine or its inhibitor as active ingredient
US8106009B2 (en) * 1997-09-26 2012-01-31 Medical Therapies Limited Pharmaceutical composition for preventing or treating ischemic diseases
AU1486801A (en) * 1999-11-15 2001-05-30 Curagen Corporation Novel growth factor polypeptides and nucleic acids encoding same
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
GB0228776D0 (en) * 2002-12-10 2003-01-15 Ares Trading Sa Splice variant
CA2735272A1 (en) * 2004-06-23 2006-01-05 Tissuegene, Inc. Nerve regeneration by transplanting cells expressing recombinant transforming growth factor superfamily protein
DK1904113T3 (en) * 2005-06-23 2016-03-21 Tissuegene Inc NEURO PROTECTIVE EFFECTIVE CONNECTION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68909254T2 (de) * 1988-01-25 1994-04-28 American Cyanamid Co Heparinbindende Gehirnmitogene.

Also Published As

Publication number Publication date
AU8258591A (en) 1992-02-27
DE69117123T2 (de) 1996-10-02
GR3019059T3 (en) 1996-05-31
JPH06217778A (ja) 1994-08-09
PT98694A (pt) 1992-07-31
NZ239357A (en) 1993-07-27
KR920004570A (ko) 1992-03-27
EP0476233A1 (en) 1992-03-25
EP0476233B1 (en) 1996-02-14
DK0476233T3 (da) 1996-03-11
US5210026A (en) 1993-05-11
AU636789B2 (en) 1993-05-06
ATE134219T1 (de) 1996-02-15
CA2049370A1 (en) 1992-02-21
DE69117123D1 (de) 1996-03-28

Similar Documents

Publication Publication Date Title
ES2085928T3 (es) Gen y secuencia proteica del mk humano.
FI873141A0 (fi) Daeggdjurs interleukin-4.
ES2056817T3 (es) Transformacion de trichoderma.
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
ES2068907T3 (es) Secuencias de nucleotidos que codifican una proteina con actividad ureasica.
ATE158816T1 (de) Expression von pace in wirtszellen und verfahren zu dessen verwendung
DE3854952T2 (de) Mykobakterielle rekombinanten und peptide
MX9203519A (es) Metodo de recombinacion para la produccion de inhibidores de proteasa de serina y secuencias de adn utiles para los mismos.
DK0666914T3 (da) Hidtil ukendt P-selectin-ligandprotein
DE3751727T2 (de) Polypeptide zur verwendung bei der diagnose von mycoplasmainfektionen bei schweinen, sowie rekombinant-dns-verfahren zur herstellung derselben
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
GB8906156D0 (en) Production and use of anthelmintic agents and protective immunogens
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 476233

Country of ref document: ES